Biotech Income Play (And MORE)

Dear Rundown Reader,

Our first reader today seems to think The Rundown is a mouthpiece for a certain media outlet: “You must be watching Fox News all the time,” he says. “Your facts are all wrong. Anyone who thinks Trump knows what he’s doing is very misinformed.

“I won’t read a line further as soon as you begin to praise that idiot Trump.”

In the words of Travis Bickle: “You talkin’ to me?” At The Rundown, we give voice to multiple readers with multiple perspectives; we believe thinking through different viewpoints is actually a healthy exercise.

Speaking of a different viewpoint: “I think President Trump acted swiftly when he found out the seriousness of the coronavirus. The problem now is the supposedly knowledgeable government team… that isn’t all that knowledgeable.

“Also, I don’t go to fake media for my news but to networks like Fox News.

“Here’s hoping we can move forward both medically and economically!”

Today we’re going to switch up the conversation… Yesterday, the president announced he’s going to leave the reopening of states up to governors. In light of that, we’d really like to know what’s happening where you live.

Other than massive shutdowns — that most all Americans are experiencing — how has COVID-19 affected your state (or country)? Overrun hospitals? Unemployment? And how would you grade your governor’s/state’s/country’s response?

Send your opinions to, TheRundownFeedback@SevenFigurePublishing.com.

Your Rundown for Friday, Apr. 17, 2020

Glimmer of Hope

In January, The Rundown recommended American biotech Gilead Sciences, Inc. (GILD) to round out your portfolio… particularly if you’re an income investor looking for a strong dividend. At the time, we noted GILD’s quarterly dividend yield of almost 4%.

We sure hope you listened.

There’s a glimmer of hope this morning from a drug trial for severely ill COVID-19 patients using Gilead’s antiviral drug remdesivir. Again, all the evidence so far is anecdotal — but still promising.

According to an article at Stat News: “The University of Chicago Medicine recruited 125 people with Covid-19 into Gilead’s two Phase 3 clinical trials. Of those people, 113 had severe disease. All the patients have been treated with daily infusions of remdesivir.”

The outcome? One hundred and eleven of the severely ill patients left the hospital within six days of starting treatment; two of the patients died.

Kathleen Mullane of the University of Chicago said of the drug trial: “We do see when patients do come in with high fevers, they do [reduce] quite quickly. We have seen people come off ventilators a day after starting therapy. So, in that realm, overall our patients have done very well.”

But Mullane warns: “Drawing any conclusions at this point is premature and scientifically unsound.”

Stat News says: “Gilead’s severe Covid-19 study includes 2,400 participants from 152 different clinical trial sites all over the world. Its moderate Covid-19 study includes 1,600 patients in 169 different centers, also all over the world.”

We’ll keep you posted as more evidence trickles in, but fingers crossed for now.

Market Rundown for Friday, Apr. 17, 2020

The S&P 500 Index is up 55 points to 2,855.

Oil is down 10% to $17.83 for a barrel of WTI.

Gold’s lost $16.70 per ounce to $1,715.80.

Bitcoin is down $125 to $7,034.54.

Send your comments and questions to, TheRundownFeedback@SevenFigurePublishing.com.

Cheers to a good weekend. We’ll talk more Monday.

For the Rundown,

Aaron Gentzler

Aaron Gentzler

You May Also Be Interested In:

Aaron Gentzler

Aaron Gentzler is the publisher of Seven Figure Publishing. He is also the editor of The Rundown and has been with Agora Financial / Seven Figure Publishing since 2005. He's been covering technology and markets for over a decade.

View More By Aaron Gentzler

LEARN TO TRADE LIKE A PRO WITH THE SEVEN FIGURE PODCAST! [CLICK HERE]